MoonLake Immunotherapeutics press release (NASDAQ:MLTX): Q2 GAAP EPS of -$0.87 misses by $0.16.
Ended the second quarter with $425.1 million in cash, cash equivalents and short-term marketable debt securities with up to an additional $425 million in non-dilutive funds remaining accessible through previously announced debt-facility
15 hours ago
1
English (US) ·